全球止血劑市場規模（按類型、產品、應用、最終用戶、區域範圍和預測）

止血劑市場規模及預測

2024 年止血劑市場規模價值 43 億美元，預計到 2032 年將達到 64.9 億美元，2026 年至 2032 年的複合年成長率為 5.30%。

止血鉗是用於在手術和緊急情況下快速有效地控制出血的材料。其作用機轉為濃縮凝血因子、附著於出血組織或將促進要素輸送至出血部位。止血鉗可以是機械式的、主動式的或被動式的。

用於治療缺乏凝血因子而引起的無法控制的大量出血、凝血障礙、外傷出血、腦出血、產後出血、大手術期間或之後的出血。

全球止血劑市場動態

影響止血劑市場的關鍵市場動態是：

關鍵市場促進因素

外科手術數量的增加：全球外科手術數量的增加是止血劑市場的主要驅動力。根據世界衛生組織 (WHO) 的數據，全球外科手術數量正在持續增加。 《柳葉刀》雜誌發表的一項研究顯示，2012 年全球共實施了 3.13 億例外科手術，預計到 2030 年將增加至 4.584 億例。外科手術數量的增加推動了對止血劑的需求，因為許多外科手術都需要良好的止血性能。

出血性疾病盛行率上升：出血性疾病盛行率上升推動了對止血劑的需求。根據世界血友病聯盟 (WFH) 的數據，全球每 10,000 人中約有 1 人患有血友病。根據 WFH 2019 年年度全球調查，全球有 324,648 人患有出血性疾病，與前一年同期比較增加了 6%。出血性疾病患者群體的不斷擴大需要在各種臨床環境中使用止血劑。

創傷和急救病例增加：創傷病例的增多，尤其是機動車事故造成的創傷，正在推動止血劑市場的發展。根據世界衛生組織（WHO）2018年《全球道路安全狀況報告》，每年約有135萬人死於道路交通事故，另有2,000萬至5,000萬人遭受非致命性傷害。許多此類傷害需要緊急止血，這增加了急診醫療和創傷護理中對止血劑的需求。

主要挑戰

止血劑價格高昂：止血劑價格昂貴，這也是一個主要障礙，尤其是在醫療資金匱乏的開發中國家。許多最新的止血劑價格昂貴，因此無力負擔的醫院和診所無法取得。這一經濟障礙阻礙了在危急情況下採用更優質的藥物，從而影響了患者的治療效果和整體市場的成長。

副作用風險：某些止血藥物的潛在副作用也限制了市場的成長。醫療保健專業人員由於擔心過敏反應和組織損傷等潛在副作用而不願使用這些產品。這些擔憂有利於現有的止血程序，並限制了新型止血材料的市場接受度和使用。

主要趨勢：

微創手術的興起：微創手術的興起對止血劑市場產生了重大影響。隨著外科技術的進步，能夠減少組織壓力並縮短恢復時間的手術越來越受到青睞。在這種情況下，止血劑至關重要，因為它們能夠控制出血，同時保護周圍組織。這項發展推動了對專為微創手術設計的新型止血劑的需求。

技術進步：止血劑的技術發展正在影響市場格局。製造商正在加大研發投入，以開發更有效、更安全的產品。具有多種作用機制的複合止血劑越來越受歡迎。這些發展不僅改善了患者的治療效果，也擴大了止血劑在各外科領域的應用。

慢性病的流行：慢性病的發生率不斷上升，加上人口老化，推動了對止血劑的需求。慢性病需要外科手術治療，因此出血控制至關重要的外科手術發生率更高。隨著全球人口老化，預計外科手術數量將會增加，從而推動止血劑市場的發展。這一趨勢凸顯了醫療保健環境中建立完善的出血控制系統的重要性。

目錄

第1章 引言

• 市場定義
• 市場區隔
• 調查方法

第2章執行摘要

• 主要發現
• 市場概覽
• 市場亮點

第3章市場概述

• 市場規模和成長潛力
• 市場趨勢
• 市場促進因素
• 市場限制
• 市場機會
• 波特五力分析

第4章 止血劑市場（按類型）

• 凝血酶類止血劑
• 明膠基止血劑
• 膠原蛋白基止血劑
• 氧化再生纖維素止血材料
• 組合止血鉗
• 纖維蛋白膠
• 其他

第5章 止血劑市場（按產品）

• 主動型
• 被動的
• 組合
• 其他

第6章 止血劑市場（依應用）

• 創傷外科
• 心血管外科
• 一般外科
• 整形外科
• 整形外科
• 神經外科

第7章區域分析

• 北美洲
• 美國
• 加拿大
• 墨西哥
• 歐洲
• 英國
• 德國
• 法國
• 義大利
• 亞太地區
• 中國
• 日本
• 印度
• 澳洲
• 拉丁美洲
• 巴西
• 阿根廷
• 智利
• 中東和非洲
• 南非
• 沙烏地阿拉伯
• 阿拉伯聯合大公國

第8章市場動態

• 市場促進因素
• 市場限制
• 市場機會
• COVID-19 市場影響

第9章 競爭態勢

• 主要企業
• 市場佔有率分析

第10章 公司簡介

• Baxter International Inc.
• Becton, Dickinson and Company（BD）
• Pfizer Inc.
• Ethicon Inc.
• B. Braun SE
• Teleflex Incorporated
• CryoLife, Inc.
• Integra LifeSciences
• Advanced Medical Solutions Group plc
• GELITA AG

第11章 市場展望與機會

• 新興技術
• 未來市場趨勢
• 投資機會

第12章 附錄

• 簡稱列表
• 來源和參考文獻

Hemostatic Agents Market Size And Forecast

Hemostatic Agents Market size was valued at USD 4.3 Billion in 2024 and is projected to reach USD 6.49 Billion by 2032, growing at a CAGR of 5.30% from 2026 to 2032.

Hemostatic agents are materials used to control bleeding quickly and effectively during surgeries or in emergency situations. They function by concentrating coagulation factors, attaching to tissues where hemorrhage has occurred, or supplying procoagulant factors to the bleeding site. Hemostatic agents are characterized as mechanical, active, or passive.

They are used to treat uncontrollable large bleeding in the absence of clotting factors, coagulation abnormalities, hemorrhage caused by trauma, cerebral hemorrhage, postpartum hemorrhage, and bleeding during or after major surgeries.

Global Hemostatic Agents Market Dynamics

The key market dynamics that are shaping the hemostatic agents market include:

Key Market Drivers

Increasing number of Surgical Procedures: The growing number of surgical operations worldwide is a major driver of the hemostatic agents market. According to the World Health Organization (WHO), the number of procedures conducted worldwide has constantly increased. According to a study published in The Lancet, 313 million surgical procedures were performed worldwide in 2012, with the figure expected to rise to 458.4 million in 2030. The increase in surgical operations, many of which require good hemostasis, is pushing up demand for hemostatic agents.

Rising Prevalence of Bleeding Disorders: The growing prevalence of bleeding diseases is driving up the demand for hemostatic agents. According to the World Federation of Hemophilia (WFH), hemophilia affects approximately one out of every 10,000 persons worldwide. In their 2019 Annual Global Survey, the WFH found 324,648 people worldwide living with bleeding disorders, a 6% rise over the previous year. The expanding patient population with bleeding disorders necessitates the use of hemostatic agents in a variety of clinical settings.

Increasing Traumatic Injuries and Emergency Cases: The increased prevalence of traumatic injuries, notably from automobile accidents, is propelling the hemostatic agents market. According to the World Health Organization's Global Status Report on Road Safety 2018, roughly 1.35 million people die each year as a result of road traffic accidents, with another 20-50 million suffering non-fatal injuries. Many of these injuries necessitate urgent hemostasis, which increases the need for hemostatic agents in emergency and trauma care settings.

Key Challenges:

High Cost of Hemostatic Agents: Hemostatic agents are expensive, which is another major barrier, especially in developing nations where funds for healthcare are few. Many modern hemostatic products are expensive, rendering them inaccessible to hospitals and clinics that cannot pay the costs. This financial barrier impedes the adoption of good medicines in critical situations, affecting patient outcomes and overall market growth.

Risk of Adverse Reactions: The potential for adverse reactions to certain hemostatic medicines also limits market growth. Healthcare experts are hesitant to utilize these products because they are concerned about potential adverse effects such as allergic responses and tissue damage. This concern leads to a preference for existing hemostasis procedures, restricting the market's acceptance and use of new hemostatic agents.

Key Trends:

Increasing Adoption of Minimally Invasive Surgeries: The growing popularity of minimally invasive operations is having a significant impact on the hemostatic agents market. As surgical techniques advance, there is an increasing preference for operations that reduce tissue stress and recuperation time. Hemostatic medicines are essential in these situations because they help control bleeding while protecting surrounding tissues. This development is generating demand for novel hemostatic agents designed specifically for minimally invasive treatments.

Technological Advancements: Technological developments in hemostatic agents are influencing the market landscape. Manufacturers are spending in R&D to develop more effective and safe products, such as enhanced formulations and delivery technologies. Combination hemostats, which have numerous mechanisms of action, are gaining traction. These developments not only improve patient outcomes but also broaden the applications of hemostatic agents across various surgical specialties.

Growing Prevalence of Chronic Diseases: The increasing frequency of chronic diseases, combined with an aging population, is driving up demand for hemostatic agents. Chronic illnesses necessitate surgical procedures, resulting in a higher incidence of surgeries where bleeding management is essential. As the world's population ages, the number of surgical procedures is predicted to increase, boosting the market for hemostatic agents. This trend underscores the importance of appropriate bleeding management systems in healthcare settings.

Global Hemostatic Agents Market Regional Analysis

Here is a more detailed regional analysis of the hemostatic agents market:

North America:

According to Verified Market Research, North America is estimated to dominate the hemostatic agents market over the forecast period. North America has a high prevalence of cardiovascular disease, which necessitates a large number of cardiac procedures that require hemostatic agents. According to the American Heart Association's 2021 Heart Disease and Stroke Statistics update, about half of all American adults suffer from cardiovascular disease. According to the report, heart disease kills over 659,000 people in the United States each year, accounting for one out of every four deaths. Also, the Society of Thoracic Surgeons states that roughly 500,000 coronary artery bypass graft surgeries are conducted each year in the United States. This large volume of cardiac surgeries increases the demand for sophisticated hemostatic agents in the region.

Furthermore, North America has a high rate of traumatic injuries, mainly from car accidents and violence, necessitating the usage of hemostatic agents in emergency situations. According to the National Center for Health Statistics, unintentional injuries are the third greatest cause of death in the United States, with around 173,040 deaths in 2019. Also, the National Trauma Institute reports that trauma accounts for 41 million emergency department visits and 2.3 million hospital admissions across the country each year. This high volume of trauma patients greatly increases the demand for hemostatic agents in North America.

Asia Pacific:

The Asia Pacific region is estimated to exhibit the highest growth during the forecast period. The Asia-Pacific region has a high rate of traffic accidents, which result in traumatic injuries requiring hemostatic agents. According to the World Health Organization's Global Status Report on Road Safety 2018, Southeast Asia and the Western Pacific regions account for 62% of all road traffic deaths. In China alone, the Ministry of Public Security reported 203,049 road traffic accidents in 2019, with 62,763 fatalities and 226,751 injuries. The increased occurrence of traumatic injuries is increasing the demand for hemostatic agents in emergency and trauma care settings throughout Asia-Pacific.

Furthermore, the Asia-Pacific region is experiencing an increase in cardiovascular disorders, which necessitate surgical procedures and the usage of hemostatic agents. According to the Asian Pacific Society of Cardiology, cardiovascular disease (CVD) causes 35% of all fatalities in the Asia Pacific region. According to the World Heart Federation, by 2030, 4.5 million people will die from cardiovascular disease in Southeast Asia alone, up from 3.6 million in 2014. The rising prevalence of cardiovascular disorders is driving up demand for hemostatic agents in heart surgery and associated treatments.

Europe:

Europe region is estimated to exhibit substantial growth during the forecast period. Europe's significant investment in healthcare infrastructure and research is fueling innovation and acceptance of improved hemostatic agents. The European Commission states that healthcare spending in the EU reached 9.9% of GDP in 2018, with an average annual increase rate of 3.0% between 2013 and 2018. Medtech Europe reports that the European medical technology market was valued at €120 billion in 2018. This strong healthcare spending and emphasis on medical technology advancement are boosting the hemostatic agents market in Europe, as hospitals and healthcare providers invest in cutting-edge technologies to improve patient outcomes.

Furthermore, Europe has a high incidence of cardiovascular illnesses, which necessitate surgical treatments and the use of hemostatic agents. The European Heart Network claims that cardiovascular disease kills 3.9 million people in Europe each year, accounting for 45% of all deaths. According to the European Society of Cardiology, more than 11 million new instances of cardiovascular disease were diagnosed in Europe year 2015. The treatment of these disorders, particularly during surgical procedures, is driving up demand for hemostatic agents in the region.

Global Hemostatic Agents Market: Segmentation Analysis

The Hemostatic Agents Market is segmented based on Type, Product, Application, End-User, and Geography.

Hemostatic Agents Market, By Type

• Thrombin-based Hemostats
• Gelatin-based Hemostats
• Collagen-based Hemostats
• Oxidized Regenerated Cellulose-based Hemostats
• Combination Hemostats
• Fibrin Sealants
• Others

Based on Type, the market is segmented into Thrombin-based, Gelatin-based, Collagen-based, Oxidized Regenerated Cellulose-based, Combination, Fibrin Sealants, and Others. The oxidized regenerated cellulose-based hemostats segment is estimated to dominate the hemostatic agents market during the forecast period. These hemostatic agents have emerged as market leaders, demonstrating their efficacy in a wide range of surgical procedures, including general surgery, cardiovascular surgery, orthopedics, and other specialties. This versatility has made them an appealing option for surgeons who face a variety of clinical settings, contributing to their dominant market position.

Hemostatic Agents Market, By Product

• Active
• Passive
• Combination
• Others

Based on Product, the market is segmented into Active, Passive, Combination, and Others. The passive segment is estimated to dominate the hemostatic agents market due to the wide range of product options and the growing popularity of technologically improved passive hemostatic solutions. These medicines are preferred for their efficacy in limiting bleeding during various surgical operations, resulting in increased acceptability among healthcare professionals. Also, the ongoing development of innovative passive hemostatic technologies by prominent manufacturers contributes to this segment's market leadership.

Hemostatic Agents Market, By Application

• Trauma
• Cardiovascular Surgery
• General Surgery
• Plastic Surgery
• Orthopedic Surgery
• Neurosurgery
• Others

Based on Application, the market is divided into Trauma, Cardiovascular Surgery, General Surgery, Plastic Surgery, Orthopedic Surgery, Neurosurgery, and Others. The general surgery segment is estimated to dominate the market over the forecast period. This dominance is driven by the growing number of surgical procedures performed worldwide, as general surgery comprises a wide range of operations that necessitate good bleeding control. The increased frequency of chronic diseases, as well as the demand for less invasive treatments, strengthen this segment, making it a vital area for hemostatic agent applications and contributing to its long-term market growth.

Hemostatic Agents Market, By End-User

• Hospitals
• Surgery Centers
• Nursing Homes
• Others

Based on End-User, the market is divided into Hospitals, Surgery Centers, Nursing Homes, and Others. The hospital segment is estimated to dominate the market over the forecast period due to the growing number of surgical procedures and the rising prevalence of chronic conditions that demand surgical interventions. Hospitals are prepared to manage difficult patients and provide comprehensive care, hence they are the principal environment for the administration of hemostatic drugs. As healthcare systems improve and expand, the need for good bleeding control in hospitals is projected to increase significantly.

Hemostatic Agents Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the World

Based on Geography, the Hemostatic Agents Market is classified into North America, Europe, Asia Pacific, and the Rest of the World. North America is estimated to dominate during the forecasted period. The region benefits from modern healthcare infrastructure, substantial healthcare spending, and a large number of surgical procedures per year. Furthermore, the existence of key market competitors and the ongoing launch of innovative hemostatic products support market growth. The growing need for technologically advanced surgical solutions reinforces North America's leadership position in this market.

Key Players

• The "Hemostatic Agents Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Baxter International, Inc., Becton, Dickinson and Company (BD), Pfizer, Inc., Ethicon, Inc., B. Braun SE, Teleflex Incorporated, CryoLife, Inc., Integra LifeSciences, Advanced Medical Solutions Group plc, and GELITA AG.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

• Hemostatic Agents Market Recent Developments
• In November 2023, Johnson & Johnson's MedTech division, Ethicon, launched Ethizia, a hemostatic sealing patch with European approval. This marks a substantial boost to the company's medical services in Europe.
• In August 2023, Vizient Inc. issued HemoSonics an Innovative Technology Contract for their Quantra hemostasis system.

TABLE OF CONTENTS

1. Introduction

• Market Definition
• Market Segmentation
• Research Methodology

2. Executive Summary

• Key Findings
• Market Overview
• Market Highlights

3. Market Overview

• Market Size and Growth Potential
• Market Trends
• Market Drivers
• Market Restraints
• Market Opportunities
• Porter's Five Forces Analysis

4. Hemostatic Agents Market, By Type

• Thrombin-based Hemostats
• Gelatin-based Hemostats
• Collagen-based Hemostats
• Oxidized Regenerated Cellulose-based Hemostats
• Combination Hemostats
• Fibrin Sealants
• Others

5. Hemostatic Agents Market, By Product

• Active
• Passive
• Combination
• Others

6. Hemostatic Agents Market, By Application

• Trauma surgery
• Cardiovascular surgery
• General surgery
• Plastic surgery
• Orthopedic surgery
• Neurosurgery

7. Regional Analysis

• North America
• United States
• Canada
• Mexico
• Europe
• United Kingdom
• Germany
• France
• Italy
• Asia-Pacific
• China
• Japan
• India
• Australia
• Latin America
• Brazil
• Argentina
• Chile
• Middle East and Africa
• South Africa
• Saudi Arabia
• UAE

8. Market Dynamics

• Market Drivers
• Market Restraints
• Market Opportunities
• Impact of COVID-19 on the Market

9. Competitive Landscape

• Key Players
• Market Share Analysis

10. Company Profiles

• Baxter International Inc.
• Becton, Dickinson and Company (BD)
• Pfizer Inc.
• Ethicon Inc.
• B. Braun SE
• Teleflex Incorporated
• CryoLife, Inc.
• Integra LifeSciences
• Advanced Medical Solutions Group plc
• GELITA AG

11. Market Outlook and Opportunities

• Emerging Technologies
• Future Market Trends
• Investment Opportunities

12. Appendix

• List of Abbreviations
• Sources and References